Zai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025 [Seeking Alpha]
Zai Lab Limited - American Depositary Shares (ZLAB)
US:NASDAQ Investor Relations:
zailaboratory.com/about/investors.php
Company Research
Source: Seeking Alpha
Follow Play 16min Summary Zai Lab Limited leverages global partnerships to commercialize approved therapies in China, focusing on oncology, autoimmune, infectious, and neurological conditions. ZLAB's leading products include VYVGART, AUGTYRO (Repotrectinib), and XACDURO, with VYVGART contributing significantly to Q2 2024 revenues. ZLAB is also developing wholly-owned IP, including ZL-1310 and ZL-1218, which could extend its global footprint beyond China. China's recent policy reforms aim to streamline drug approvals and expand insurance coverage, boosting ZLAB's growth prospects, especially in oncology. I believe ZLAB trades at a compelling valuation. Its impressive growth prospects and potential profitability by 2025 make it a "Strong Buy." yongyuan Zai Lab Limited ( NASDAQ: ZLAB ) develops therapies across oncology, autoimmune, infectious, and neurological conditions. The company collaborated with leading companies to create approved products like VYVGART, AUGTY
Show less
Read more
Impact Snapshot
Event Time:
ZLAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZLAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZLAB alerts
High impacting Zai Lab Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ZLAB
News
- Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024 [Yahoo! Finance]Yahoo! Finance
- Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024Business Wire
- Zai Lab Limited (ZLAB): Top ADR Stock According to Hedge Funds [Yahoo! Finance]Yahoo! Finance
- Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024Business Wire
- Zai Lab Announces Participation in September Investor ConferencesBusiness Wire
ZLAB
Earnings
- 8/6/24 - Miss
ZLAB
Sec Filings
- 9/19/24 - Form 144
- 9/5/24 - Form 4
- 9/3/24 - Form 144
- ZLAB's page on the SEC website